North American Report

DelveInsight Evaluates a Robust Liposarcoma Pipeline as 15+ Companies to Set Foot in the Domain

 Breaking News
  • No posts were found

DelveInsight Evaluates a Robust Liposarcoma Pipeline as 15+ Companies to Set Foot in the Domain

March 02
22:20 2023
DelveInsight Evaluates a Robust Liposarcoma Pipeline as 15+ Companies to Set Foot in the Domain

DelveInsight’s, “Liposarcoma Pipeline Insight 2023,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Liposarcoma pipeline landscape. It covers the Liposarcoma pipeline drug profiles, including Liposarcoma clinical trials and nonclinical stage products. It also covers the Liposarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Liposarcoma Emerging drugs, the Liposarcoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Liposarcoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Liposarcoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Liposarcoma clinical trials studies, Liposarcoma NDA approvals (if any), and product development activities comprising the technology, Liposarcoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Liposarcoma Pipeline Report

 

  • Over 15+ Liposarcoma companies are evaluating 15+ Liposarcoma pipeline therapies in various stages of development, and their anticipated acceptance in the Liposarcoma market would significantly increase market revenue.

 

  • The leading Liposarcoma Companies includes Karyopharm Therapeutics, Rain Therapeutics, Pfizer, Sanofi, Incyte Corporation, Macrogenics, Adaptimmune, Merck KGaA, GlaxoSmithKline, Novartis Oncology, Immune Design, Syndivia, TerSera Therapeutics, and others.

 

  • Promising Liposarcoma Pipeline Therapies includes Trabectedin, Dexamethasone, Dacarbazine, RAIN-32, HDM201, LEE011, Selinexor, IPI-504, Yondelis, Cabazitaxel, MGCD516, and others.

 

  • The Liposarcoma Companies and academics are working to assess challenges and seek opportunities that could influence Liposarcoma R&D. The Liposarcoma pipeline therapies under development are focused on novel approaches to treat/improve Liposarcoma.

 

Request a sample and discover the recent breakthroughs happening in the Liposarcoma Pipeline landscape @ Liposarcoma Pipeline Outlook Report

 

Liposarcoma Overview

Liposarcomas are rare type of malignant tumors of fatty tissue. They are the second most common type of soft-tissue sarcoma. Liposarcoma can occur in fat cells in any part of the body, but most cases occur in the muscles of the limbs or in the abdomen. Liposarcomas are typically found in adults, typically between the ages of 40 and 60, and are rare in children. Liposarcoma occurs more often in men than women. Liposarcoma risk factors may include radiation, family cancer syndromes, a damaged lymph system, and/or exposure to certain chemicals.

 

Liposarcoma Emerging Drugs Profile

 

  • RAIN-32: Rain Therapeutics

RAIN-32 (milademetan) is a small molecule based oral inhibitor of mouse double minute 2 (MDM2). MDM2 is a critical regulator of tumor protein 53 (p53), which is known as the “guardian of the genome”. RAIN-32 is in Phase III clinical studies for the treatment of Liposarcoma.

 

  • Selinexor: Karyopharm Therapeutics

Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. The molecule functions by binding with, and inhibiting, the nuclear export protein, XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus. Selinexor, with the brand name XPOVIO, has been approved by the USFDA for relapsed or refractory multiple myeloma, relapsed or refractory diffuse large B-cell lymphoma (DLBCL), and in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The drug is in Phase III clinical studies for the treatment of Liposarcoma.

 

For further information, refer to the detailed Liposarcoma Drugs Launch, Liposarcoma Developmental Activities, and Liposarcoma News, click here for Liposarcoma Ongoing Clinical Trial Analysis

 

Liposarcoma Pipeline Therapeutics Assessment

There are approx. 15+ key companies which are developing the therapies for Liposarcoma. The companies which have their Liposarcoma drug candidates in the most advanced stage, i.e. Phase III include, Rain Therapeutics.

 

Liposarcoma Pipeline Segmentation

 

Phases

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates 

 

Route of Administration

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

 

Molecule Types

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Find out more about the Liposarcoma Pipeline Segmentation, Therapeutics Assessment, Liposarcoma Emerging Drugs @ Liposarcoma Treatment Landscape

 

Scope of the Liposarcoma Pipeline Report

 

  • Coverage- Global

 

  • Liposarcoma Companies- Karyopharm Therapeutics, Rain Therapeutics, Pfizer, Sanofi, Incyte Corporation, Macrogenics, Adaptimmune, Merck KGaA, GlaxoSmithKline, Novartis Oncology, Immune Design, Syndivia, TerSera Therapeutics, and others.

 

  • Liposarcoma Pipeline Therapies includes Trabectedin, Dexamethasone, Dacarbazine, RAIN-32, HDM201, LEE011, Selinexor, IPI-504, Yondelis, Cabazitaxel, MGCD516, and others.

 

  • Liposarcoma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration 

 

Dive deep into rich insights for drugs for Liposarcoma Pipeline Companies and Therapies, click here @ Liposarcoma Unmet Needs and Analyst Views

 

Table of Content

 

  1. Introduction
  2. Executive Summary
  3. Liposarcoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Liposarcoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. RAIN-32: Rain Therapeutics
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Cabazitaxel: Sanofi
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. Ribociclib: Novartis Oncology
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. SDV-1101: Syndivia
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Liposarcoma Key Companies
  21. Liposarcoma Key Products
  22. Liposarcoma- Unmet Needs
  23. Liposarcoma- Market Drivers and Barriers
  24. Liposarcoma- Future Perspectives and Conclusion
  25. Liposarcoma Analyst Views
  26. Appendix

 

Got Queries? Find out the related information on Liposarcoma Mergers and acquisitions, Liposarcoma Licensing Activities @ Liposarcoma Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/